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comorbidities on the risk of developing
hospitalised pneumonia in England
J. Campling1*, D. Jones1, J. D. Chalmers2, Q. Jiang3, A. Vyse1, H. Madhava1, G. Ellsbury1 and M. Slack4Abstract
Background: UK specific data on the risk of developing hospitalised CAP for patients with underlying comorbidities
is lacking. This study compared the likelihood of hospitalised all-cause community acquired pneumonia (CAP) in
patients with certain high-risk comorbidities and a comparator group with no known risk factors for pneumococcal
disease.
Methods: This retrospective cohort study interrogated data in the Hospital Episodes Statistics (HES) dataset
between financial years 2012/13 and 2016/17. In total 3,078,623 patients in England (aged ≥18 years) were linked to
their hospitalisation records. This included 2,950,910 individuals with defined risk groups and a comparator group of
127,713 people who had undergone tooth extraction with none of the risk group diagnoses. Risk groups studied
were chronic respiratory disease (CRD), chronic heart disease (CHD), chronic liver disease (CLD), chronic kidney
disease (CKD), diabetes (DM) and post bone marrow transplant (BMT). The patients were tracked forward from year
0 (2012/13) to Year 3 (2016/17) and all diagnoses of hospitalised CAP were recorded. A Logistic regression model
compared odds of developing hospitalised CAP for patients in risk groups compared to healthy controls. The
model was simultaneously adjusted for age, sex, strategic heath authority (SHA), index of multiple deprivation (IMD),
ethnicity, and comorbidity. To account for differing comorbidity profiles between populations the Charlson
Comorbidity Index (CCI) was applied. The model estimated odds ratios (OR) with 95% confidence intervals of
developing hospitalised CAP for each specified clinical risk group.
Results: Patients within all the risk groups studied were more likely to develop hospitalised CAP than patients in
the comparator group. The odds ratios varied between underlying conditions ranging from 1.18 (95% CI 1.13, 1.23)
for those with DM to 5.48 (95% CI 5.28, 5.70) for those with CRD.
Conclusions: Individuals with any of 6 pre-defined underlying comorbidities are at significantly increased risk of
developing hospitalised CAP compared to those with no underlying comorbid condition. Since the likelihood varies
by risk group it should be possible to target patients with each of these underlying comorbidities with the most
appropriate preventative measures, including immunisations.
Keywords: Pneumonia, Pneumococcus, Hospitalised community acquired pneumonia (CAP), Risk groups, Linkage,
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Community acquired pneumonia (CAP) remains a
major cause of morbidity and mortality, resulting in
a major impact on the UK and European healthcare
systems. Across Europe, annual inpatient care for
pneumonia accounts for approximately €5.7 billion
of healthcare expenditure [1]. Pneumonia is respon-
sible for more hospital admissions and bed days than
any other respiratory disease in the UK [2]. Hospita-
lised CAP carries a mortality rate of 5–19% rising to
more than 30% for those admitted to intensive care
[3–5] and results in 29,000 deaths per annum.
Streptococcus pneumoniae is the most commonly
identified cause of CAP; however, the microbio-
logical aetiology is not identified in approximately
50% of cases [6, 7].
There have been a number of studies that have
shown patients with a range of underlying comor-
bidities are at an increased risk of developing IPD
[8–12]. Van Hoek et al. used national surveillance
data for IPD in England and Wales in combination
with Hospital Episodes Statistics (HES) data to
demonstrate an increased odds ratio (OR) for hos-
pitalisation and death from IPD in patients with
specific risk groups in the UK [12]. The risk varied
by underlying comorbidity; with the most important
risk factors predicting IPD being chronic liver dis-
ease, immunosuppression and chronic respiratory
disease. There have to date been a limited number
of studies that have examined the risk of develop-
ing CAP using healthcare utilisation database re-
cords [13, 14]. However, UK specific evidence on
the risk of developing hospitalised CAP in key risk
groups is lacking. This retrospective pilot study
compared the likelihood of being hospitalised with
all-cause community acquired pneumonia in pa-
tients with pre-specified high-risk comorbidities and
a comparator group with no known risk factors for
CAP.
Methods
This retrospective cohort study interrogated data
contained within the Hospital Episodes Statistics
(HES) dataset between financial years 2012/13 and
2015/16 [15]. 2012/13 will now be referred to as
Year 0, 2013/14 as Year 1, 2014/15 as Year 2 and
2015/16 as Year 3. HES is a data warehouse con-
taining clinical information of all admissions, bed
days, length of admission, outpatient appointments,
attendances at Accident and Emergency Depart-
ments at National Health Service (NHS) hospitals
in England, discharge diagnoses and hospital death.
It is a record-based system covering all NHShospitals in England. These data are collected to
allow hospitals to be paid for the care that they de-
liver. The primary diagnosis and other clinical con-
ditions are specified using the tenth revision of the
International Classification of Diseases version 10
(ICD-10) [16].
Data was extracted from the HES database for
adults ≥18 yrs. based on the ICD-10 codes identified.
Each patient had his or her own unique NHS identi-
fier which ensured patients were not double counted
within the analysis. NHS Digital applies a strict statis-
tical disclosure control in accordance with the HES
protocol, to all published HES data. This suppresses
small numbers to prevent people identifying them-
selves and others, to ensure patient confidentiality is
maintained.
Patients were grouped together according to their
underlying comorbidity (i.e. clinical risk group)
which was identified by the relevant ICD-10 codes
(Table 3 in Appendix). We chose not to stratify by
severity of underlying comorbidity in order to sim-
plify the analysis. They were: Bone Marrow Trans-
plant (BMT), Chronic Respiratory Disease, Diabetes
Mellitus (DM), Chronic Kidney Disease (CKD),
Chronic Heart Disease (CHD) and Chronic Liver
Disease (CLD). These risk factors were selected be-
cause they are included in the conditions for which
pneumococcal polysaccharide vaccine (PPV23) is
recommended by the UK Department of Health
[17].
The clinical risk group populations were defined by
the following criteria:
Inclusion criteria for clinical risk group popula-
tions: 1) A risk group diagnosis (Table 3 in Appen-
dix- ICD-10 CODE) in Year 0. 2) ≥ 18 years at point
of risk group diagnosis. 3) No diagnosis of pneumo-
nia (Table 3 in Appendix- ICD-10 CODE) in either
the primary or secondary position in Year 0. 4) No
evidence of in-patient death in Year 0. Exclusion
criteria for clinical risk group populations: No
pneumonia diagnosis in either the primary or sec-
ondary position in Year 0 or Year 1, but with pneu-
monia diagnosis in Year 2 and/or Year 3.
Identification of Pneumonia cases: A pneumonia
diagnosis (Table 3 in Appendix- ICD-10 CODE) in
either the primary or secondary position in Year 1-
Year 3. Exclusion of Pneumonia cases: Healthcare
Acquired Pneumonia (HCAP) excluded if the pneu-
monia diagnosis was made within 48 h of the admis-
sion) [18].
Each risk cohort was determined independently;
therefore, some patients may have been grouped
into multiple risk groups. To ensure that all pneu-
monia presenting in secondary care was captured
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codes were in either the primary or secondary pos-
ition. The ICD-10 codes chosen to identify risk
groups reflected the codes used by van Hoek et al.
in their study of the impact of underlying comor-
bidities on invasive pneumococcal disease [12]. The
comparator group consisted of healthy individuals
admitted to hospital for a tooth extraction proced-
ure in Year 0 (Table 3 in Appendix for list of ICD-
10 codes). After careful consideration, we chose in-
dividuals admitted to hospital for a tooth extrac-
tion, who did not have any of the following
underlying comorbidities (leukaemia, multiple mye-
loma, BMT, HIV, sickle cell, asplenic / splenic dys-
function, CHD, CKD, CLD, DM, malignant disease
treatment on immunosuppressive chemotherapy or
radiotherapy), as the comparator group. This elect-
ive procedure was selected as it was not believed to
be directly associated with any underlying co-
morbidity associated with developing hospitalised
CAP, but we excluded any individuals within the
comparator group who had any comorbid condition
associated with an increased risk of developing
pneumococcal infection, as defined by the UK De-
partment of Health, for the duration of the study
(Year 0 – Year 3) [17].
Individuals were identified and tracked forward from
Year 0 to Year 3 and all diagnoses of hospitalised CAP
were recorded. All eligible individuals within the clinical
risk groups and the comparator group were followed
from Year 0 to Year 3. All episodes of hospitalised CAP
that occurred from Year 1 to Year 3 in clinical risk
group patients and the comparator group were identi-
fied. Information on the patients’ age, gender, ethnicity,
index of multiple deprivation (IMD) and strategic health
authority (SHA) was also extracted.
The study design is shown in Fig. 1.Fig. 1 Study design assessing odds ratio of hospitalised CAP for risk groupStatistical analysis
The outcome of interest was the diagnosis of hospita-
lised CAP. The odds ratio was calculated as odds of
developing hospitalised CAP during Year 1 to Year 3
for patients within a risk group comparing to that for
a “healthy” comparator cohort with no risk group
diagnosis as defined by the UK Department of Health
[17].
A logistic regression model was used to compare
the odds of developing hospitalised CAP within a
risk group vs within the ‘healthy’ comparator group.
The model was simultaneously adjusted with the age,
sex, strategic heath authority (SHA), index of mul-
tiple deprivation (IMD), ethnicity of patients, and co-
morbidity. To account for the fact that the
comorbidity profile may have differed between the
populations the Charlson Comorbidity Index (CCI)
was used [19]. The model estimated odds ratios
(OR) with 95% confidence intervals of developing
hospitalised CAP for each specified clinical risk
group.
Results
A total of 3,078,623 patient records were distributed
into 6 risk groups and the comparator group. The
number of patients within each group is shown in
Table 1.
The observed number of cases of hospitalised CAP in
each clinical risk group and the comparator group who
developed hospitalised CAP between Years 0 to Year 3 is
shown in Table 1. The largest clinical risk groups identi-
fied in the HES database were approximately 1.3 million
patients with CHD; the smallest was approximately 6000
BMT patients.
The odds ratio of developing hospitalised CAP for
patients in the clinical risk groups compared with
hospitalised CAP cases in the patients with nos compared with “healthy” comparators
Table 1 Number of patients in risk groups and comparators who did or did not develop CAP
Group Number of Patients Who Developed
CAP (%)
Number of Patients Who Did Not Develop
CAP (%)
Total Number of
Patients
CHD 277,179 (21.5%) 1,104,335 (78.5%) 1,291,531
CKD 89,144 (26.3%) 249,384 (73.7%) 338,541
CLD 19,516 (19.9%) 78,798 (80.1%) 98,317
CRD 156,899 (33.7%) 309,071 (66.3%) 465,983
DM 12,072 (16.1%) 629,303 (83.7%) 750,379
BMT 1627 (26.4%) 4532 (73.6%) 6159
Comparator Group (tooth
extraction)
3203 (2.5%) 124,510 (97.5%) 127,713
Total – – 3,078,623
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These odds ratios (as approximations of relative risk)
are reported as are unadjusted and adjusted for po-
tential confounders. For example, the approximate
unadjusted risk of CAP in the CHD risk group com-
pared to the comparator group is more than 10-fold
higher (OR = 10.62; 95% CI: 10.25–11.00). After
adjusting for both gender and CCI the OR falls to
3.15. The final model included all factors simultan-
eously (age, gender, CCI, ethnicity, SHA and IMD),
patients with CHD are about twice as likely to
present with CAP compared to those without CHD
(OR = 1.87; 95% CI = 1.80–1.94). For all risk groups
studied the factor having the largest influence on the
odds of developing CAP was the CCI.
Patients within all the risk groups studied were
more likely to develop hospitalised CAP than pa-
tients in the comparator group. Patients with CRD
had the highest likelihood, with an odds ratio of
5.48 (95% CI 5.28–5.70). The group studied with theTable 2 Odds Ratio of risk of hospitalised CAP compared to compa
Confounder Comparison of CAP vs Non CAP (Odds Ratios)
CHD CKD CLD
ORa (95% CI) ORa (95% CI) ORa (9
Overall (unadjusted) 10.62 (10.25, 11.00 13.90 (13.41, 14.40) 9.63 (9
Gender: Male 13.57 (12.88, 14.28) 14.85 (14.09, 15.65) 10.98 (1
Female 8.28 (7.89, 8.69) 12.81 (12.20, 13.46) 8.23 (7
Adjusting for Gender 10.44 (10.08; 10.82) 13.74 (13.25, 14.24) 9.40 (9
Adjusting for Gender
& CCI
3.15 (3.03, 3.27) 2.18 (2.09, 2.27) 2.71 (2
Adjusting for Gender,
Age & CCI
1.86 (1.79, 1.93) 2.20 (2.12, 2.30) 3.56 (3
Adjusting for Gender,
Age, CCI, Ethnicicty,
STHA & IMD
1.87 (1.80, 1.94) 2.22 (2.13, 2.32) 3.43 (3
aOdds of CAP in the risk group compared to the comparatorsecond highest odds of developing CAP was post
BMT (odds ratio 5.46 (95% CI 5.05–5.90). These two
clinical risk groups had a five-fold increase of devel-
oping hospitalised CAP compared to the comparator
group. Patients with DM had the lowest odds of de-
veloping hospitalised CAP (odds ratio 1.18 (95% CI
1.13–1.23).
Discussion
This is the first study utilising HES to quantify the
increased likelihood of hospitalised CAP among adults
with certain underlying comorbidities in England.
HES is an administrative database that contains infor-
mation on all episodes of hospital care in England.
Patient notes are reviewed by coding clerks who as-
sign the ICD-10 codes based on diagnoses recorded
by the attending physician. Variabilit in both the
quality and consistency of the coding is considered
likely. HES also does not contain information on la-
boratory testing so aetiology of each case cannot berators for each potential confounder
CRD DM BMT
5% CI) ORa (95% CI) ORa (95% CI) ORa (95% CI)
.27, 10.01) 19.73 (19.04, 20.45) 7.48 (7.22, 7.75) 13.96 (13.06, 14.92)
0.37, 11.61) 22.62 (21.47, 23.82) 8.38 (7.95, 8.82) 14.92 (13.43, 16.56)
.81, 8.67) 16.92 (16.11, 17.77) 6.53 (6.22, 6.86) 12.35 (11.32, 13.47)
.05, 9.77) 19.39 (18.71, 20.09) 7.34 (7.08,7.61) 13.34 (12.47, 14.26)
.60, 2.82) 5.55 (5.34, 5.76) 1.02 (0.98, 1.07) 3.39 (3.16, 3.64)
.41, 3.72) 5.61 (5.40, 5.83) 1.18 (1.14, 1.23) 5.37 (4.99, 5.79)
.29, 3.59) 5.48 5.28, 5.70) 1.18 (1.13, 1.23) 5.46 (5.05, 5.90)
Fig. 2 Odds ratio of risk of developing hospitalised CAP for each clinical risk group
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used in conjunction with a diagnosis of pneumonia
depending on the level of information available, code
J18 is by far the most common of the pneumonia
diagnoses and is used when the causative organism is
either unknown or unspecified. The most commonly
identified causative organism for hospital CAP is S.
pneumoniae [20, 21]. Despite its limitations HES is
frequently used for research in the UK due to its
universal coverage, long period of data collection
and ability to create nationally representative cohorts
that can be followed over time. Whilst there are
concerns regarding the accuracy of coding, epi-
demiological studies using HES are considered in-
formative with HES recently used to study the
impact of pneumococcal conjugate vaccine on pneu-
monia, sepsis and otitis media hospital admissions in
England [22–24].
Selecting an appropriate comparator group re-
quires careful consideration. We needed a group of
healthy individuals but required them to have had a
data entry in the HES database to analyse their
health status. We considered people who hadattended hospital with broken bones / elective hip &
knee replacement but were concerned about the
high level of associated comorbidities. We therefore
chose individuals admitted to hospital for a tooth
extraction who did not have any of the underlying
comorbidities as the comparator group. We believed
this procedure was unlikely to be associated with
the risk groups under investigation. It has been sug-
gested however that impaired oral hygiene is a risk
factor for developing pneumonia therefore the
choice of this comparator may have resulted in an
underestimation of the impact of the comorbidities
studied [25].
For all risk groups studied the factor having the
largest influence on the odds of developing CAP was
the CCI. Given that the CCI is strongly associated
with the other confounding factors that we adjusted
for this finding was unsurprising. However, even
after adjusting for the CCI the effects of the under-
lying comorbidities studied remained significant. The
impact of gender on the likelihood of developing
CAP is well established and has been reported previ-
ously [26].
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risk groups increases the likelihood of a hospital
admission for CAP, with the risk varying by condi-
tion. The odds ratios varied between 1.18 (95% CI
1.13, 1.23) for DM to 5.48 (95% CI 5.28, 5.70) for
those with CRD, indicating that not only do pa-
tients with a risk group diagnosis have an elevated
risk of developing hospitalised CAP but also that
the underlying diagnosis determines the magnitude
of this risk.
Van Hoek and colleagues used the national sur-
veillance programme which monitors IPD in Eng-
land and linked it with the HES database to
determine the odds of developing IPD in patients
with specific clinical risk groups [12]. The most im-
portant risk factors that predicted IPD were chronic
liver disease, immunosuppression and chronic re-
spiratory disease. While van Hoek’s results are not
directly comparable to our study, the observed pat-
terns in the odds ratios across the risk groups are
similar.
Our results are comparable to previous studies
within this area in Germany and the United States,
which quantify the risk of developing pneumonia in
individuals with underlying comorbidities [13, 14].
Shea et al. [14] utilising data from the United
States found patients with chronic lung disease had
a rate ratio of 6.6 (95% CI 6.6, 6.7) compared to a
healthy population. Patients with chronic heart dis-
ease had a rate ratio of 3.8 (95% CI 3.8, 3.80). The
lower rate ratios derived in our study may reflect a
higher threshold for hospitalisation of cases of CAP
in the UK, where many cases are treated in primary
care.
As with any epidemiological study which relies on
diagnostic coding it is possible that, due to the large
amount of data within the HES database, some mis-
classification may have occurred. We therefore chose
to interrogate HES from financial year 2012/13 be-
cause the reliability of data from this time point im-
proved following changes to the NHS payment
process [27].
While we accounted for several relevant con-
founders, we were unable to adjust for frailty.
Frailty, an age-related decline in reserve and func-
tion, [28] often coexists with chronic diseases [29].
and will increase the likelihood of hospitalisation
with CAP. Since frailty factors are not coded in
HES we were unable to determine the contribution
of the comorbidity or degree of frailty to hospita-
lised CAP.
Due to the nature of the coding system it was
challenging to differentiate between hospitalised CAP
and healthcare- acquired pneumonia (HCAP). Weattempted to control for this by excluding cases of
pneumonia that developed at least 48 h post admis-
sion (i.e. meeting the definition for HCAP) [30]
however this was again dependant on the accuracy
with which patients were coded. Patients with a risk
group diagnosis may be at an increased risk of de-
veloping HCAP compared to those who have not
been admitted with an underlying comorbidity.
Therefore, it is possible that the presence of HCAP
cases within the dataset may have slightly over-
inflated the reported odds ratios.
We categorised patients based on ICD-10 codes
into one of six risk groups. However, many patients
will have more than one underlying comorbidity.
The risk of developing CAP increases when patients
have an increasing number of comorbidities, a
phenomenon known as “risk stacking” [14, 31].
There is evidence that immunocompetent adults
with two or more underlying risk groups (multimor-
bidity) have a higher risk of developing pneumococ-
cal disease and patients with three or more at-risk
conditions are at similar risk of developing pneumo-
coccal infection as those with immunosuppressive
conditions [32]. The role of severity or chronicity of
the underlying comorbidity was outside the scope of
this study but should be considered by subsequent
relevant studies.
We have not accounted for losing patients from the
study due to mortality. The HES data warehouse only
includes records of patients’ contacts with hospitals in
England. Mortality data would therefore only reflect
death in hospital during an admission, rather than 30-
day mortality.
Conclusions
Individuals with any of 6 pre-defined underlying comor-
bidities are at significantly increased risk of developing
hospitalised CAP compared to those with no underlying
comorbid condition. The odds ratios varied between
underlying conditions ranging from 1.18 (95% CI 1.13,
1.23) for those with DM to 5.48 (95% CI 5.28, 5.70) for
those with CRD.
This work begins to address the data gap in terms
of defining the burden of CAP in adults with risk
factors and compliments work undertaken by van
Hoek et al. on IPD. Our study highlights the im-
portance of protecting ‘at risk’ patients against CAP
and the need to consider the role of relevant vac-
cines in this context, including pneumococcal and
influenza vaccine. Since the likelihood varies by risk
group it should be possible to target each with the
most appropriate preventative measures, including
immunisations.
Appendix
Table 3 List of ICD-10 codes used to identify patients and associated activity
# Cohort Name ICD-10 Codesa
1. Pneumonia J12, J13, J14, J15, J16, J17, J18
2. Chronic respiratory disease J40, J41, J42, J43, J44, J47, J6, J7, J80, J81, J82, J83, J84, Q30, J31, Q32, Q33, Q34, Q35, Q36, Q37
3. Chronic heart disease I05, I06, I07, I08, I09, I11, I12, I13, I20, I21, I22, I25, I27, I28, I3, I40, I41, I42, I43, I44, I45, I47, I48, I49, I50, I51, I52, Q2
4. Chronic kidney disease N00, N01, N02, N03, N04, N05, N07, N08, N11, N12, N14, N15, N16, N18, N19, N25, Q60, Q61
5. Chronic liver disease K70, K71, K72, K73, K74, K75, K76, K77, P78.8, Q44
6. Diabetes mellitus E10, E11, E12, E13, E14, E24, G59.0, G63.2, G73.0, G99.0, N08.3, O24, P70.0, P70.1, P70.2
7. Post BMT Z94.8
8. Tooth Procedure F09: Surgical removal of tooth
F10: Simple extraction of tooth
aICD-10 codes taken from Rozenbaum et al. [11]
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BMT: Bone marrow transplant; CAP: Community acquired pneumonia;
CCI: Charlson comorbidity index; CHD: Chronic heart disease; CI: 95%
confidence interval; CKD: Chronic kidney disease; CLD: Chronic liver disease;
CRD: Chronic respiratory disease; DM: Diabetes mellitus; HCAP: Healthcare
acquired pneumonia; HES: Hospital episode statistics; ICD-10: International
Statistical Classification of Diseases and Related Health Problems – 10th
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